연구동향 분석
박사

The therapeutic strategies using direct gene manipulation by silencing or editing the mutated gene for Charcot-Marie-Tooth disease : The therapeutic strategies for the most commonly inherited neurological disorder = 유전자를 편집하거나 돌연변이가 발생된 유전자의 발현을 억제하는 직접적인 유전자 조작을 이용한 샤르코 마리 투스 질환을 위한 여러가지 치료적 전략들 : 가장 흔한 유전성 퇴행성 신경질환을 위한 여러가지 치료적 전략들

이지수 2019년

논문상세정보
인용/피인용
' The therapeutic strategies using direct gene manipulation by silencing or editing the mutated gene for Charcot-Marie-Tooth disease : The therapeutic strategies for the most commonly inherited neurological disorder = 유전자를 편집하거나 돌연변이가 발생된 유전자의 발현을 억제하는 직접적인 유전자 조작을 이용한 샤르코 마리 투스 질환을 위한 여러가지 치료적 전략들 : 가장 흔한 유전성 퇴행성 신경질환을 위한 여러가지 치료적 전략들' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Charcot-Marie-Tooth disease (CMT)
  • crispr/cas9
  • microrna
  • small interfering rna (sirna)
  • therapy
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
311 0

0.0%

' The therapeutic strategies using direct gene manipulation by silencing or editing the mutated gene for Charcot-Marie-Tooth disease : The therapeutic strategies for the most commonly inherited neurological disorder = 유전자를 편집하거나 돌연변이가 발생된 유전자의 발현을 억제하는 직접적인 유전자 조작을 이용한 샤르코 마리 투스 질환을 위한 여러가지 치료적 전략들 : 가장 흔한 유전성 퇴행성 신경질환을 위한 여러가지 치료적 전략들' 의 참고문헌

  • van Paassen, B.W., A.J. van der Kooi, K.Y. van Spaendonck-Zwarts, C. Verhamme, F. Baas, and M. de Visser. 2014. PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies. Orphanet J Rare Dis 9:38.
  • Zuckerman JE, Davis ME. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov. 2015; 14(12):843-56.
  • Zhao HT, Damle S, Ikeda-Lee K, Kuntz S, Li J, Mohan A, Kim A, Hung G, Scheideler MA, Scherer SS, Svaren J, Swayze EE, Kordasiewicz HB (2018) PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. J Clin Invest 128:359-368.
  • Yun B, Anderegg A, Menichella D, Wrabetz L, Feltri ML, Awatramani R (2010) MicroRNA-deficient Schwann cells display congenital hypomyelination. J Neurosci 30:7722-8.
  • Wang C, Ji B, Cheng B, Chen J, Bai B (2014) Neuroprotection of microRNA in neurological disorders. Biomed Rep. 2:611-619.
  • Verrier JD, Semple-Rowland S, Madorsky I, Papin JE, Notterpek L (2010) Reduction of Dicer impairs Schwann cell differentiation and myelination. J Neurosci Res 88:2558-68.
  • Verrier JD, Lau P, Hudson L, Murashov AK, Renne R, Notterpek L (2009) Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a. Glia 57:1265-79.
  • Verhamme, C., R.H. King, A.L. ten Asbroek, J.R. Muddle, M. Nourallah, R. Wolterman, F. Baas, and I.N. van Schaik. 2011. Myelin and axon pathology in a long-term study of PMP22-overexpressing mice. J Neuropathol Exp Neurol 70:386-398.
  • Verhamme C, King RH, ten Asbroek AL, Muddle JR, Nourallah M, Wolterman R, Baas F, van Schaik IN. (2011) Myelin and axon pathology in a long-term study of PMP22-overexpressing mice. J Neuropathol Exp Neurol 70:386-98.
  • Valentijn LJ, Baas F, Wolterman RA, Hoogendijk JE, van den Bosch NH, Zorn I, Gabre ls-Festen AW, de Visser M, Bolhuis PA. Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A. Nat Genet. 1992;2(4):288-91.
  • Suter, U., G.J. Snipes, R. Schoener-Scott, A.A. Welcher, S. Pareek, J.R. Lupski, R.A. Murphy, E.M. Shooter, and P.I. Patel. 1994. Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J Biol Chem 269:25795-25808.
  • Sun X, He S, Wara AKM, Icli B, Shvartz E, Tesmenitsky Y, Belkin N, Li D, Blackwell TS, Sukhova GK, Croce K, Feinberg MW (2014) Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 114:32-40
  • Sontheimer EJ, Carthew RW (2005) Silence from within: endogenous siRNAs and miRNAs. Cell 122:9-12.
  • Slobodin, B., R. Han, V. Calderone, J. Vrielink, F. Loayza-Puch, R. Elkon, and R. Agami. 2017. Transcription Impacts the Efficiency of mRNA Translation via Cotranscriptional N6-adenosine Methylation. Cell 169:326-337 e312.
  • Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet 1974: 6 (2): 98–118.
  • Skre H (1974) Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 6:98-118.
  • Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA (2016) microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine 12:34-42.
  • Sereda, M.W., G. Meyer zu Horste, U. Suter, N. Uzma, and K.A. Nave. 2003. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9:1533-1537.
  • Sereda, M., I. Griffiths, A. Puhlhofer, H. Stewart, M.J. Rossner, F. Zimmerman, J.P. Magyar, A. Schneider, E. Hund, H.M. Meinck, U. Suter, and K.A. Nave. 1996. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16:1049-1060.
  • Sereda MW, Meyer zu H rste G, Suter U, Uzma N, Nave KA (2003) Therapeutic administration of progesterone antagonist in a model of Charcot-Marie- Tooth disease (CMT-1A). Nat Med 9:1533-7.
  • Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, Linsley PS, Aronin N, Xu Z, Zamore PD. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2006;2(9):e140.
  • Sargiannidou, I., A. Kagiava, S. Bashiardes, J. Richter, C. Christodoulou, S.S. Scherer, and K.A. Kleopa. 2015. Intraneural GJB1 gene delivery improves nerve pathology in a model of X-linked Charcot-Marie-Tooth disease. Ann Neurol 78:303-316.
  • Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69(1):22-33.
  • Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, Mendell JR (2005) NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 65:681-9.
  • Sahenk Z, Galloway G, Edwards C, Malik V, Kaspar BK, Eagle A, Yetter B, Forgie A, Tsao D, Lin JC (2010) TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in Trembler J mice. Exp Neurol 224:495-506.
  • Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, Chen L, Braganza C, Montgomery C, Mendell JR (2014) AAV1.NT-3 gene therapy for charcot-marie-tooth neuropathy. Mol Ther 22:511-521.
  • Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013;9:562–71.
  • Robertson AM, Huxley C, King RH, Thomas PK. Development of early postnatal peripheral nerve abnormalities in Trembler-J and PMP22 transgenic mice. J Anat. 1999;195 (Pt 3):331-9.
  • Robertson AM, Huxley C, King RH, Thomas PK (1999) Development of early postnatal peripheral nerve abnormalities in Trembler-J and PMP22 transgenic mice. J Anat 195:331-9.
  • Robaglia-Schlupp, A., J. Pizant, J.C. Norreel, E. Passage, D. Saberan-Djoneidi, J.L. Ansaldi, L. Vinay, D. Figarella-Branger, N. Levy, F. Clarac, P. Cau, J.F. Pellissier, and M. Fontes. 2002. PMP22 overexpression causes dysmyelination in mice. Brain 125:2213-2221.
  • Ran, F.A., L. Cong, W.X. Yan, D.A. Scott, J.S. Gootenberg, A.J. Kriz, B. Zetsche, O. Shalem, X. Wu, K.S. Makarova, E.V. Koonin, P.A. Sharp, and F. Zhang. 2015. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186-191.
  • Raeymaekers, P., V. Timmerman, E. Nelis, P. De Jonghe, J.E. Hoogendijk, F. Baas, D.F. Barker, J.J. Martin, M. De Visser, P.A. Bolhuis, and et al. 1991. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1:93-97.
  • Pereira JA, Baumann R, Norrm n C, Somandin C, Miehe M, Jacob C, L hmann T, Hall-Bozic H, Mantei N, Meijer D, Suter U (2010) Dicer in Schwann cells is required for myelination and axonal integrity. J Neurosci 30:6763-75
  • Perea, J., A. Robertson, T. Tolmachova, J. Muddle, R.H. King, S. Ponsford, P.K. Thomas, and C. Huxley. 2001. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum Mol Genet 10:1007-1018.
  • Passage, E., J.C. Norreel, P. Noack-Fraissignes, V. Sanguedolce, J. Pizant, X. Thirion, A. Robaglia-Schlupp, J.F. Pellissier, and M. Fontes. 2004. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10:396-401.
  • Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Font s M (2004) Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10:396-401.
  • Park, J., K. Lim, J.S. Kim, and S. Bae. 2017. Cas-analyzer: an online tool for assessing genome editing results using NGS data. Bioinformatics 33:286-288.
  • Pareyson, D., M.M. Reilly, A. Schenone, G.M. Fabrizi, T. Cavallaro, L. Santoro, G. Vita, A. Quattrone, L. Padua, F. Gemignani, F. Visioli, M. Laura, D. Radice, D. Calabrese, R.A. Hughes, A. Solari, T. Cmt, and C.-T. groups. 2011. Ascorbic acid in CharcotMarie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 10:320-328.
  • Pareyson D, Saveri P, Pisciotta C (2017) New developments in Charcot-Marie-Tooth neuropathy and related diseases. Curr Opin Neurol 30:471-480.
  • Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laur M, Radice D, Calabrese D, Hughes RA, Solari A; CMT-TRIAAL; CMT-TRAUK groups (2011) Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 10:320-8.
  • Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8(7):654-667.
  • Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471-86.
  • Pantera, H., J.J. Moran, H.A. Hung, E. Pak, A. Dutra, and J. Svaren. 2018. Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer. Hum Mol Genet
  • Okamoto Y, Pehlivan D, Wiszniewski W, Beck CR, Snipes GJ, Lupski JR, Khajavi M. Curcumin facilitates a transitory cellular stress response in Trembler-J mice. Hum Mol Genet. 2013 Dec 1;22(23):4698-705. doi: 10.1093/hmg/ddt318. Epub 2013 Jul 11.
  • Notterpek L, Shooter EM, Snipes GJ. Upregulation of the endosomal-lysosomal pathway in the trembler-J neuropathy. J Neurosci. 1997; 17(11):4190-200.
  • Norreel, J.C., M. Jamon, G. Riviere, E. Passage, M. Fontes, and F. Clarac. 2001. Behavioural profiling of a murine Charcot-Marie-Tooth disease type 1A model. Eur J Neurosci 13:1625-1634.
  • Nobbio, L., D. Visigalli, D. Radice, E. Fiorina, A. Solari, G. Lauria, M.M. Reilly, L. Santoro, A. Schenone, D. Pareyson, and C.-T. Group. 2014. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker. Brain 137:1614-1620.
  • Nicks J, Lee S, Harris A, Falk DJ, Todd AG, Arredondo K, Dunn WA Jr, Notterpek L. Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice. Neurobiol Dis. 2014;70:224-36.
  • N brega C, Nascimento-Ferreira I, Onofre I, Albuquerque D, Hirai H, D glon N, de Almeida LP. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice. PLoS One. 2013;8(1):e52396.
  • Murphy SM, Laura M, Fawcett K, Pandraud A, Liu YT, Davidson GL, Rossor AM, Polke JM, Castleman V, Manji H, Lunn MP, Bull K, Ramdharry G, Davis M, Blake JC, Houlden H, Reilly MM. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry. 2012;83(7):706-10.
  • Meyer zu Horste, G., T. Prukop, D. Liebetanz, W. Mobius, K.A. Nave, and M.W. Sereda. 2007. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 61:61-72.
  • Meyer zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW (2007) Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 61:61-72.
  • Maier, M., F. Castagner, P. Berger, and U. Suter. 2003. Distinct elements of the peripheral myelin protein 22 (PMP22) promoter regulate expression in Schwann cells and sensory neurons. Mol Cell Neurosci 24:803-817.
  • Magyar, J.P., R. Martini, T. Ruelicke, A. Aguzzi, K. Adlkofer, Z. Dembic, J. Zielasek, K.V. Toyka, and U. Suter. 1996. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J Neurosci 16:5351-5360.
  • Lupski, J.R., R.M. de Oca-Luna, S. Slaugenhaupt, L. Pentao, V. Guzzetta, B.J. Trask, O. Saucedo-Cardenas, D.F. Barker, J.M. Killian, C.A. Garcia, A. Chakravarti, and P.I. Patel. 1991. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66:219-232.
  • Lopez-Anido, C., Y. Poitelon, C. Gopinath, J.J. Moran, K.H. Ma, W.D. Law, A. Antonellis, M.L. Feltri, and J. Svaren. 2016. Tead1 regulates the expression of Peripheral Myelin Protein 22 during Schwann cell development. Hum Mol Genet 25:3055-3069.
  • Long, C., J.R. McAnally, J.M. Shelton, A.A. Mireault, R. Bassel-Duby, and E.N. Olson. 2014. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345:1184-1188.
  • Lewis, R.A., M.P. McDermott, D.N. Herrmann, A. Hoke, L.L. Clawson, C. Siskind, S.M. Feely, L.J. Miller, R.J. Barohn, P. Smith, E. Luebbe, X. Wu, M.E. Shy, and G. Muscle Study. 2013. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 70:981-987.
  • Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, Feely SM, Miller LJ, Barohn RJ, Smith P, Luebbe E, Wu X, Shy ME; Muscle Study Group (2013) High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 70:981-7.
  • Letzen BS, Liu C, Thakor NV, Gearhart JD, All AH, Kerr CL (2010) MicroRNA expression profiling of oligodendrocyte differentiation from human embryonic stem cells. PLoS One. 5:e10480.
  • Lee, J., S.C. Jung, J. Joo, Y.R. Choi, H.W. Moon, G. Kwak, H.K. Yeo, J.S. Lee, H.J. Ahn, N. Jung, S. Hwang, J. Rheey, S.Y. Woo, J.Y. Kim, Y.B. Hong, and B.O. Choi. 2015. Overexpression of mutant HSP27 causes axonal neuropathy in mice. J Biomed Sci 22:43.
  • Lee JS, Chang EH, Koo OJ, Jwa DH, Mo WM, Kwak G, Moon HW, Park HT, Hong YB, Choi BO (2017) Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo. Neurobiol Dis 100:99-107.
  • Lee J, Jung SC, Joo J, Choi YR, Moon HW, Kwak G, Yeo HK, Lee JS, Ahn HJ, Jung N, Hwang S, Rheey J, Woo SY, Kim JY, Hong YB, Choi BO (2015) Overexpression of mutant HSP27 causes axonal neuropathy in mice. J Biomed Sci 22:43.
  • Layzer JM, Mccaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. RNA. 2004;10(5):766–771.
  • Kosicki, M., K. Tomberg, and A. Bradley. 2018. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 36:765-771.
  • Komyathy K, Neal S, Feely S, Miller LJ, Lewis RA, Trigge G, Siskind CE, Shy ME, Ramchandren S. Anterior tibialis CMAP amplitude correlations with impairment in CMT1A. Muscle Nerve. 2013;47(4):493-496.
  • Kim, S., D. Kim, S.W. Cho, J. Kim, and J.S. Kim. 2014. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24:1012-1019.
  • Kim, K., S.W. Park, J.H. Kim, S.H. Lee, D. Kim, T. Koo, K.E. Kim, J.H. Kim, and J.S. Kim. 2017. Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration. Genome Res 27:419-426.
  • Kim, D., S. Bae, J. Park, E. Kim, S. Kim, H.R. Yu, J. Hwang, J.I. Kim, and J.S. Kim. 2015. Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nat Methods 12:237-243, 231 p following 243.
  • Khajavi M, Inoue K, Wiszniewski W, Ohyama T, Snipes GJ, Lupski JR. Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. Am J Hum Genet. 2005;77(5):841-50.
  • Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Font s M (2007) Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord 17:248-53.
  • Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ, Lebeche D (2013) Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2:e000078.
  • Kagiava, A., and K.A. Kleopa. 2018. Intrathecal Delivery of Viral Vectors for Gene Therapy. Methods Mol Biol 1791:277-285.
  • Kagiava, A., I. Sargiannidou, G. Theophilidis, C. Karaiskos, J. Richter, S. Bashiardes, N. Schiza, M. Nearchou, C. Christodoulou, S.S. Scherer, and K.A. Kleopa. 2016. Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy. Proc Natl Acad Sci U S A 113:E2421-2429.
  • Kagiava, A., C. Karaiskos, J. Richter, C. Tryfonos, G. Lapathitis, I. Sargiannidou, C. Christodoulou, and K.A. Kleopa. 2018. Intrathecal gene therapy in mouse models expressing CMT1X mutations. Hum Mol Genet 27:1460-1473.
  • Jones, E.A., C. Lopez-Anido, R. Srinivasan, C. Krueger, L.W. Chang, R. Nagarajan, and J. Svaren. 2011. Regulation of the PMP22 gene through an intronic enhancer. J Neurosci 31:4242-4250.
  • Ji W, Sun B, Su C (2017) Targeting MicroRNAs in Cancer Gene Therapy. Genes (Basel) 8. pii: E21
  • Ino D, Iino M (2016) In vivo gene transfer to Schwann cells in the rodent sciatic nerve by electroporation. J Vis Exp 115.
  • Huxley, C., E. Passage, A.M. Robertson, B. Youl, S. Huston, A. Manson, D. Saberan-Djoniedi, D. Figarella-Branger, J.F. Pellissier, P.K. Thomas, and M. Fontes. 1998. Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet 7:449-458.
  • Huxley, C., E. Passage, A. Manson, G. Putzu, D. Figarella-Branger, J.F. Pellissier, and M. Fontes. 1996. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 5:563-569.
  • Huxley C, Passage E, Robertson AM, Youl B, Huston S, Manson A, Sab ran-Djoniedi D, Figarella-Branger D, Pellissier JF, Thomas PK, Font s M (1998) Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet 7:449-58.
  • Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, Font s M (1996) Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 5:563-9.
  • Heller KN, Mendell JT, Mendell JR, Rodino-Klapac LR (2017) MicroRNA-29 overexpression by adeno-associated virus suppresses fibrosis and restores muscle function in combination with micro-dystrophin. JCI Insight 2. pii: 93309.
  • Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980;103 (2): 259–280
  • Gonzalez, S., R.N. Fernando, C. Perrin-Tricaud, and N. Tricaud. 2014. In vivo introduction of transgenes into mouse sciatic nerve cells in situ using viral vectors. Nat Protoc 9:1160-1169.
  • Gokey NG, Srinivasan R, Lopez-Anido C, Krueger C, Svaren J (2012) Developmental regulation of microRNA expression in Schwann cells. Mol Cell Biol. 32:558-568.
  • Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15(2):65-77.
  • Fledrich R, Stassart RM, Klink A, Rasch LM, Prukop T, Haag L, Czesnik D, Kungl T, Abdelaal TA, Keric N, Stadelmann C, Br ck W, Nave KA, Sereda MW. Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nat Med. 2014;20(9):1055-61.
  • Fledrich R, Stassart RM, Klink A, Rasch LM, Prukop T, Haag L, Czesnik D, Kungl T, Abdelaal TA, Keric N, Stadelmann C, Br ck W, Nave KA, Sereda MW (2014) Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie- Tooth disease 1A. Nat Med 20:1055-61.
  • Dickson KM, Bergeron JJ, Shames I, Colby J, Nguyen DT, Chevet E, Thomas DY, Snipes GJ. Association of calnexin with mutant peripheral myelin protein-22 ex vivo: a basis for "gain-of-function" ER diseases. Proc Natl Acad Sci U S A. 2002;99(15):9852-7.
  • Dickson KM, Bergeron JJ, Shames I, Colby J, Nguyen DT, Chevet E, Thomas DY, Snipes GJ (2002) Association of calnexin with mutant peripheral myelin protein-22 ex vivo: a basis for "gain-of-function" ER diseases. Proc Natl Acad Sci U S A 99:9852-7.
  • Chung KW, Suh BC, Shy ME, Cho SY, Yoo JH, Park SW, Moon H, Park KD, Choi KG, Kim S, Kim SB, Shim DS, Kim SM, Sunwoo IN, Choi BO. Different clinical and magnetic resonance imaging features between Charcot-Marie-Tooth disease type 1A and 2A. Neuromuscul Disord. 2008;18(8):610-8.
  • Chumakov I, Milet A, Cholet N, Primas G, Boucard A, Pereira Y, Graudens E, Mandel J, Laffaire J, Foucquier J, Glibert F, Bertrand V, Nave KA, Sereda MW, Vial E, Guedj M, Hajj R, Nabirotchkin S, Cohen D (2014) Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis 9:201
  • Chuai, G.H., Q.L. Wang, and Q. Liu. 2017. In Silico Meets In Vivo: Towards Computational CRISPR-Based sgRNA Design. Trends Biotechnol 35:12-21.
  • Chittoor VG, Sooyeon L, Rangaraju S, Nicks JR, Schmidt JT, Madorsky I, Narvaez DC, Notterpek L. (2013) Biochemical characterization of protein quality control mechanisms during disease progression in the C22 mouse model of CMT1A. ASN Neuro 5:e00128.
  • Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 2016;4(7):35-50.
  • Chance, P.F., M.K. Alderson, K.A. Leppig, M.W. Lensch, N. Matsunami, B. Smith, P.D. Swanson, S.J. Odelberg, C.M. Disteche, and T.D. Bird. 1993. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 72:143-151.
  • Bremer J, O'Connor T, Tiberi C, Rehrauer H, Weis J, Aguzzi A (2010) Ablation of Dicer from murine Schwann cells increases their proliferation while blocking myelination. PLoS One 5:e12450.
  • Bosse, F., G. Zoidl, S. Wilms, C.P. Gillen, H.G. Kuhn, and H.W. Muller. 1994. Differential expression of two mRNA species indicates a dual function of peripheral myelin protein PMP22 in cell growth and myelination. J Neurosci Res 37:529-537.
  • Boerkoel, C.F., H. Takashima, C.A. Garcia, R.K. Olney, J. Johnson, K. Berry, P. Russo, S. Kennedy, A.S. Teebi, M. Scavina, L.L. Williams, P. Mancias, I.J. Butler, K. Krajewski, M. Shy, and J.R. Lupski. 2002. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 51:190-201.
  • Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K, Russo P, Kennedy S, Teebi AS, Scavina M, Williams LL, Mancias P, Butler IJ, Krajewski K, Shy M, Lupski JR (2002) Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 51:190-201.
  • Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-97.
  • Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, P r on Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, Mandel J, Milet A, Hajj R, Boudiaf L, Scart-Gr s C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D (2014) An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis 9:199.
  • Askou AL, Alsing S, Holmgaard A, Bek T, Corydon TJ (2018) Dissecting microRNA dysregulation in age-related macular degeneration: new targets for eye gene therapy. Acta Ophthalmol 96:9-23.
  • Arthur-Farraj, P., K. Wanek, J. Hantke, C.M. Davis, A. Jayakar, D.B. Parkinson, R. Mirsky, and K.R. Jessen. 2011. Mouse schwann cells need both NRG1 and cyclic AMP to myelinate. Glia 59:720-733.
  • Alves S, Nascimento-Ferreira I, Auregan G, Hassig R, Dufour N, Brouillet E, Pedroso de Lima MC, Hantraye P, Pereira de Almeida L, D glon N. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One. 2008;3(10):e3341.
  • Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. Development 132:4653-62.
  • Adlkofer, K., R. Frei, D.H. Neuberg, J. Zielasek, K.V. Toyka, and U. Suter. 1997. Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy. J Neurosci 17:4662-4671.